Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications resulted in substantial weight loss. The trial, call

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said. Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.